| 查看: 1951 | 回复: 5 | |||
[交流]
【讨论】非索非那定的市场情况
|
|
求：非索非那定的 一、产品研发背景 1. 原研厂家 2. 研发时间与研究立意 3.国外的上市与销售情况 二、与现有竞争产品的比较 三、国内市场情况 1.批文数量及厂家（含规格） 2. 历史销售情况及分析 3.国内主要生产厂家的销售情况 |
回复此楼» 猜你喜欢
可能上不了岸？有条件的可以考虑其他出路
已经有0人回复
-
分子对接相关经验分享
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有165人回复
-
分子对接相关经验分享
已经有0人回复
-
使用MolAICal生成小分子CHARMM力场拓扑和参数文件
已经有0人回复
-
2026生物医药产业发展大会
已经有0人回复
-
国青中了
已经有23人回复
-
扩散模型生成分子目前痛点，改进方向有哪些，论文创新性卡住了现在
已经有0人回复
-
求解答药物生成模型痛点以及创新点，扩散模型创新
已经有0人回复
-
:D多个国家或地区的农药法规&登记情况查询网站
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 现在国内有那几家在生产毒莠定？市场情况如何？
已经有4人回复
» 抢金币啦！回帖就可以得到:
-
安徽工程大学徐珍珍课题组招聘博士后
+1/332
-
经济危机不是生产过剩
+1/134
-
澳门大学智慧城市物联网国重“基础设施智能监测”及“智慧城市”研究方向博士后招聘
+1/134
-
澳门大学智慧城市物联网国重”基础设施智能监测“及”智慧城市“研究方向博士生招生
+1/134
-
南开大学环境科学与工程学院 环境与人体健康方向 招博士研究生、硕士研究生各1名
+1/87
-
原子层沉积（ALD）等微纳代工服务：18817872921
+1/81
-
四川大学卢伟课题组招收2027年秋季入学博士生2名
+1/75
-
华南师范大学王耀教授招收2027年审核制博士
+1/49
-
华南师范大学（211）- 光电科学与工程学院招收物理学（一流学科）2027级博士
+1/44
-
香港城市大学（东莞）雷进程课题组博士研究生、研究助理招聘
+1/38
-
华南理工大学黄哲昊课题组招收博士研究生
+2/34
-
热分析测试
+1/32
-
电子科技大学（深圳）高等研究院Beng Hau Tan 课题组现面向海内外公开招聘多名博士后
+1/32
-
澳大利亚皇家墨尔本理工招收phd
+1/30
-
北京化工大学杨琪教授 邱介山教授，招收博士1-2名，2027年秋季入学
+1/28
-
赤藓糖醇-聚合物复合相变材料的潜热长期储存
+1/14
-
浙大许军课题组招聘
+1/13
-
中国科学院大学陈凯凯课题组招收2027级博士生
+2/8
-
东北师范大学国家杰青团队招收2027年“申请考核制”博士研究生
+1/3
-
清华大学深圳国际研究生院-智慧健康建筑实验室-2027年博士招生
+1/1
2楼2011-03-18 12:51:27
★ ★ ★
warlen(金币+1): 谢谢参与 2011-03-18 15:54:09
空城若虚(金币+40): 非常感谢！ 2011-03-18 20:13:20
caoyuan521(金币+2): 谢谢参与！ 2011-03-18 21:04:15
warlen(金币+1): 谢谢参与 2011-03-18 15:54:09
空城若虚(金币+40): 非常感谢！ 2011-03-18 20:13:20
caoyuan521(金币+2): 谢谢参与！ 2011-03-18 21:04:15
|
Fexofenadine hydrochloride Cas number: 153439-40-8, 138452-21-8 - General description: Fexofenadine (trade names Allegra, Telfast, Fastofen, Tilfur, Vifas, Telfexo, Allerfexo) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine (trade names include Triludan and Seldane), an antihistamine which caused QT interval prolongation, potentially leading to cardiac arrhythmia. It has been described as both second-generation[3] and third-generation antihistamine. The older antihistaminic agent terfenadine was found to metabolize into the related carboxylic acid, fexofenadine. Fexofenadine was found to retain all of the biological activity of its parent while giving fewer adverse reactions in patients, so terfenadine was replaced in the market by its metabolite.[8] Fexofenadine was originally synthesized in 1993 by Massachusetts-based biotechnology company Sepracor, which then sold the development rights to Hoechst Marion Roussel (now part of Sanofi-Aventis), and was later approved by the Food and Drug Administration (FDA) in 1996. AMRI holds the patents to the intermediates and production of fexofenadine HCl along with Roussel. Since that time, it has achieved blockbuster drug status with global sales of $1.87B USD in 2004 (with $1.49B USD coming from the United States). AMRI received royalty payments from Aventis that enabled the growth of AMRI. On January 25, 2011, the FDA approved over-the-counter sales of fexofenadine in the United States, with Sanofi-Aventis' version expected to become available on March 4, 2011. I. Originator:Aventis Pharma, Sepracor; Marketer: ViroPharma; Reference patent: JP 1996502022; WO 9321156; II. Main Competitors in U.S: N021963 Yes FEXOFENADINE HYDROCHLORIDE SUSPENSION; ORAL 30MG/5ML ALLEGRA SANOFI AVENTIS US -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076236 AB No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 60MG;120MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A079043 No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 180MG;240MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076298 AB No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 60MG;120MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE IMPAX PHARMS III. China Domestic Market I suggest you to look through the SFDA website to get related informations. It is not difficult. IV. The market information is not easy to acquire. I suggest you to purchase IMS data or BMI data. |
3楼2011-03-18 13:36:14
4楼2011-03-18 20:10:17
我主要是为了赚BB5楼2011-03-18 21:35:10
6楼2011-03-29 08:47:19
